Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers October 20, 2014
Pharmacy Choice - News - Generic Drugs - October 20, 2014

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 47     Next >>     Go To Page:

10/20/14 - Amgen Announces Positive Top-Line Results From Phase 3 Study Evaluating The Efficacy And Safety Of Biosimilar Candidate ABP 501 Compared With...
By a News Reporter-Staff News Editor at Biotech Business Week Amgen announced its Phase 3 study evaluating efficacy and safety of biosimilar candidate ABP 501 compared with Humira in patients with moderate-to-severe plaque psoriasis met its primary endpoint. "Results from Amgen's biosimilar Phase 3 plaque psoriasis study met the primary endpoint
10/20/14 - Generic and Innovative Drugs Market in Ukraine 2014: Development Forecasts for 2014-2019, New Report Launched
Market Research Reports, Inc. has announced the addition of Generic and innovative drugs market in Ukraine 2014: Development forecasts for 2014-2019 research report to their website http://www.MarketResearchReports.comLewes, DE 10/20/2014 This publication is a complete source of fresh data and valuable analysis of essential aspects of t
10/20/14 - IGI Laboratories To Hold Conference Call For 3rd Quarter 2014 Results
IGI Laboratories, Inc., a New Jersey based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:15 pm ET on Thursday, October 23, 2014 to discuss the 3rd quarter 2014 results. The Company invites you to listen to the call by dialing 1-888-346-3479. International participants should call 1-412-902-4260.
10/20/14 - IGI Laboratories, Inc. Appoints Steven Koehler To Board Of Directors
By a News Reporter-Staff News Editor at Pharma Business Week IGI Laboratories, Inc., a New Jersey- based specialty generic pharmaceutical company, announced that it has appointed Steven Koehler to its Board of Directors. Prior to this role, Mr. Koehler served as the Vice President, Corporate Controller of Schering-Plough Corporation, where he als
10/20/14 - Mylan Launches Generic Combivir
By a News Reporter-Staff News Editor at AIDS Weekly Mylan Inc. announced the U.S. launch of its Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, which is the generic version of Viiv's Combivir. Lamivudine and Zidovudine Tablets USP, 150 mg/300 mg, had U.S. sales of approximately $118.5 million for the 12 months ending June 30, 2014, accordin
10/20/14 - NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice
NDA Partners provides legal services, including research, expert reports and expert witness and testimony, to top law firms and their clients in cases involving complex issues such as product liability, patent infringement, generic competition, and regulatory agency process. About NDA Partners NDA Partners is a strategy consulting firm specializing
10/20/14 - Nobel laureate to help drive Baiyunshan's 'golden spear' [China Daily: US Edition]
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, a Chinese pharmaceutical company, has roped in the services of well-known Nobel laureate Ferid Murad to produce and market generic variants of popular erectile dysfunction medicine Viagra. The two products will hit the market next month and would be first generic versions of Viagra in China, acco
10/20/14 - Overview of Biosimilar Market in Japan 2014-2016
By a News Reporter-Staff News Editor at Pharma Business Week Research and Markets has announced the addition of the "The Overview of Biosimilar Market in Japan" report to their offering. The market for biosimilars is expected be around 4.5 billion JPY in 2012. A total of only three products including human growth hormone and erythropoietin were o
10/20/14 - Teva to Report Third Quarter 2014 Financial Results on October 30, 2014
By a News Reporter-Staff News Editor at Pharma Business Week Teva Pharmaceutical Industries Ltd. announced that it will release its third quarter 2014 financial results on Thursday, October 30, 2014 at 7:00 a.m. ET. Teva will host a conference call and live webcast on the same day, at 8:00 a.m. ET to discuss its third quarter 2014 results and ove
10/19/14 - Competition Commission of India may okay Sun-Ranbaxy deal with rider [India Business] [Times of India]
By: Rajat Arora NEW DELHI: Sun Pharma and Ranbaxy Laboratories may have to give price and supply commitments, which include ensuring price caps on some drugs for a specific period, before the Competition Commission of India gives its approval to their proposed merger. In April, Sun Pharma agreed to acquire Ranbaxy from its Japanese parent Daiichi S
10/19/14 - Nobel laureate to help drive Baiyunshan's 'golden spear' [EMBIN (Emerging Markets Business Information News]
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, a Chinese pharmaceutical company, has roped in the services of well-known Nobel laureate Ferid Murad to produce and market generic variants of popular erectile dysfunction medicine Viagra. The two products will hit the market next month and would be first generic versions of Viagra in China, acco
10/19/14 - OTC Daily Alert Stock Watch - Intellipharmaceutics International Inc. (NASDAQ: IPCI)
Today's alerts include: Intellipharmaceutics International Inc.; FRIDAY CLOSE $2.74. Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled and targeted release oral solid dosage drugs in Canada. Intellipharmaceutics International Inc. is headquartered in Toronto,...
10/19/14 - Ranbaxy to pay $40 million to settle Texas Medicaid pricing litigation [EMBIN (Emerging Markets Business Information News]
Generic drugmaker Ranbaxy Laboratories Ltd said it has agreed to pay $39.75 million to settle litigation concerning its participation in Texas Medicaid, the US federal-state healthcare program for people with low incomes. The litigation related to the manner in which Ranbaxy historically reported pricing data to Texas Medicaid for some drugs, Ranba
10/18/14 - Nobel laureate to help drive Baiyunshan's 'golden spear' [China Daily: Africa Weekly]
Photo taken on Nov 13, 2013 in Milan, Italy shows Viagra, the medication pill to treat erectile dysfunction. Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd, a Chinese pharmaceutical company, has roped in the services of well-known Nobel laureate Ferid Murad to produce and market generic variants of popular erectile dysfunction medicine Viagra.
10/18/14 - Nobel laureate to help drive Baiyunshan's 'golden spear' [China Daily: Hong Kong Edition]
Photo taken on Nov 13, 2013 in Milan, Italy shows Viagra, the medication pill to treat erectile dysfunction. Guangzhou Baiyunshan Pharmac eu tical Holdings Co Ltd, a Chinese pharmaceutical company, has roped in the services of well-known Nobel laureate Ferid Murad to produce and market generic variants of popular erectile dysfunction medicine Viagr
10/17/14 - Findings from Fukuoka University Provides New Data on Nephrology [Contrast between innovator drug- and generic drug-induced renal dysfunction on...
Findings from Fukuoka University Provides New Data on Nephrology. By a News Reporter-Staff News Editor at Health& Medicine Week Investigators discuss new findings in Nephrology. The news reporters obtained a quote from the research from Fukuoka University, "Therefore, the aim of this study was to compare contrast media- induced renal dysfunction
10/17/14 - HORIZON PHARMA PLC FILES (8-K) Disclosing Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Pursuant to the asset purchase agreement, we acquired the rights and other assets related to PENNSAID 2% in the United States including, among other things, the investigational new drug application, or IND, and new drug application, or NDA, for PENNSAID 2%, Nuvo's interests in patents covering PENNSAID 2% in the United States and certain regulatory
10/17/14 - Noven Files Patent Infringement Lawsuit Against Actavis [Global Data Point]
The lawsuit was filed as a result of Actavis submitting an Abbreviated New Drug Application to the U.S. Food and Drug Administration in which Actavis is seeking approval to market and sell a generic version of Brisdelle capsules prior to the expiration of the Patents. Under the Hatch-Waxman Act, because Noven filed this patent infringement lawsuit
10/17/14 - Patent for Hair Loss Drug Propecia Expires in the UK - Dr Fox Online Clinic
Propecia is a prescription only medicine and currently costs around 40 per month, however this could reduce very substantially in the coming weeks. The price of the generic alternative to branded Viagra fell by about 90% when it's patent expired last year. Dr Tony Steele from online hair loss clinic http://www.doctorfox.co.uk said:.
10/17/14 - Therapeutic Proteins International Wins 'Innovation of the Year' Award by Honeywell [Manufacturing Close - Up]
Therapeutic Proteins International, reported that it has received the' Innovation of the Year' award sponsored by Honeywell at the Global Generics and Biosimilars Awards held in Paris on Oct. 7. In its release, TPI said the accolade recognized its accomplishments in biopharmaceutical manufacturing and continued commitment to solutions in the indust
10/16/14 - Actavis Confirms Generic Quillivant XR Patent Litigation
NEW YORK CITY- Actavis plc confirmed Thursday that it has filed an Abbreviated New Drug Application or ANDA with the U.S. Food and Drug Administration or FDA seeking approval to market Methylphenidate Hydrochloride for Extended-release Oral Suspension, 5 mg/mL. Tris Pharma, Inc. filed suit against Actavis on October 15, 2014 in the U.S. District Co
10/16/14 - Actavis Confirms Generic Quillivant XR Patent Challenge
Actavis' ANDA product is a generic version of Pfizer and Tris Pharma's Quillivant XR , which is a central nervous system stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder. Tris Pharma, Inc. filed suit against Actavis on October 15, 2014 in the U.S. District Court for the District of Delaware seeking to prevent Acta
10/16/14 - Attorney General Abbott Recovers $39.75 Million for State of Texas, U.S. Medicaid Program
Texas Attorney General Greg Abbott has resolved an enforcement action against Ranbaxy, a generic drug manufacturer. The agreement resolves the State's lawsuit under the Texas Medicaid Fraud Prevention Act against Ranbaxy Pharmaceuticals, Inc., Ranbaxy Laboratories, Inc., Ranbaxy USA, Inc. and Ranbaxy, Inc. for fraudulently reporting inflated drug p
10/16/14 - Biosimilars Market - Overview and a Global Outlook
Transparency Market Research includes new market research report "Biosimilars Market" to its huge collection of research reports.Albany, NY 10/16/2014 Unlike generic drugs in which the active ingredients of the drugs are identical, biosimilars are identical to, but are not copies of the original biologic drug. Introduction of biosimilars in t
10/16/14 - CAGW Releases Poll Results Regarding Use of Biosimilar Drugs
A legal framework to approve biosimilars was established in Europe in 2003, and they have been used safely since the first medication was approved in 2006. However, four years after the passage of PPACA, not a single biosimilar has been approved by the FDA. CAGW's poll shows that 78 percent of voters agree that healthcare costs are out of control a
Articles(s): 1 - 25 of 47     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

The Diversion of Controlled Substances and the Law
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415